Previous 10 | Next 10 |
Trevena (NASDAQ: TRVN ): Q1 GAAP EPS of -$0.06 in-line. More news on: Trevena, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Trevena Reports First Quarter 2020 Results FDA review of oliceridine NDA ongoing; PDUFA date August 7, 2020 IND filing for novel S1P modulator (TRV045) in 1H 2021; ongoing collaboration with NIH to evaluate for epilepsy and pain -- Company to host conference call today, ...
CHESTERBROOK, Pa., May 01, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial re...
Overview of clinical and nonclinical data to date for oliceridine; includes efficacy data in hard- and soft- tissue surgeries, safety / tolerability data in high-risk patients CHESTERBROOK, Pa., April 23, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical com...
Trevena, Inc. (TRVN) Q4 2019 Results Earnings Conference Call March 12, 2020, 08:00 AM ET Company Participants Robert Yoder - Senior Vice President, Chief Business Officer Carrie Bourdow - President and Chief Executive Officer Mark Demitrack - Senior Vice President, Chief Medical...
The following slide deck was published by Trevena, Inc. in conjunction with their 2019 Q4 earnings Read more ...
Trevena (NASDAQ: TRVN ): Q4 GAAP EPS of -$0.07 beats by $0.02 . More news on: Trevena, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
PDUFA date of August 7, 2020 for IV oliceridine; FDA considers NDA resubmission complete Initiated proof-of-concept studies for acute migraine (TRV250) and opioid use disorder (TRV734) Announces NIH collaboration to evaluate TRV045 for epilepsy Updated guidance on extend...
The following slide deck was published by Trevena, Inc. in conjunction with this Read more ...
CHESTERBROOK, Pa., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has resubmitted its New Drug...
News, Short Squeeze, Breakout and More Instantly...
2024-04-02 07:15:05 ET JMP Securities analyst issues MARKET OUTPERFORM recommendation for TRVN on April 2, 2024 05:40AM ET. The previous analyst recommendation was Market Outperform. TRVN was trading at $0.4 at issue of the analyst recommendation. Historical Analyst Re...
TRV045, novel S1P receptor modulator for chronic pain and epilepsy, advances toward important milestones in both non-clinical and clinical studies Company announces reduction of OLINVYK commercial support and review of alternatives for OLINVYK CHESTERBROOK, Pa., April 01, 2024 (GL...
CHESTERBROOK, Pa., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. ("Trevena" or the "Company") (NASDAQ:TRVN), a biopharmaceutical company focus...